All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
FLAIR trial: MRD-directed ibrutinib + venetoclax vs FCR in patients with CLL
|
FLAIR (ISRCTN01844152), a multicenter, open-label, parallel-group, randomized, controlled, phase III trial, evaluated the efficacy and safety of Ibr + Ven, with treatment duration guided by MRD status, compared to FCR in patients with previously untreated CLL.1 Results from the trial were published in the New England Journal of Medicine by Talha et al.1 |
| Key learnings |
| With a median follow-up of 43.7 months, the estimated 3-year PFS and OS for Ibr + Ven vs FCR were 97.2% vs 76.8 and 98% vs 93%, respectively. OS and PFS was improved across all subgroups except patients with mutated IGHV. |
| At 3 years, 58.0% of patients treated with Ibr + Ven had stopped therapy due to uMRD. After 5 years, 65.9% of patients had uMRD in BM and 92.7% had uMRD in PB. |
| The percentage of patients with cardiac SAEs was higher with Ibr + Ven vs FCR (10.7% vs 0.4%). |
| These results provide evidence for the efficacy and safety of MRD-directed Ibr + Ven therapy, which could facilitate personalized treatment durations for patients with untreated CLL. Subgroup analysis highlights the benefits for patients who may have poorer outcomes with available treatments. |
Abbreviations: BM, bone marrow; CLL, chronic lymphocytic leukemia; FCR, fludarabine-cyclophosphamide-rituximab; Ibr, ibrutinib; OS, overall survival; PB, peripheral blood; PFS, progression-free survival; Ven, venetoclax; SAE, serious adverse event; uMRD, undetectable measurable residual disease.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Which of the following do you consider a key challenge when implementing the BrECADD regimen for the treatment of Hodgkin lymphoma?
